| (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy AP Kiess, IL Minn, G Vaidyanathan, RF Hobbs, A Josefsson, C Shen, ... Journal of Nuclear Medicine 57 (10), 1569-1575, 2016 | 128 | 2016 |
| Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ... Nuclear medicine and biology 40 (1), 52-59, 2013 | 113 | 2013 |
| Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ... Journal of nuclear medicine 55 (4), 650-656, 2014 | 89 | 2014 |
| Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET G Vaidyanathan, D McDougald, J Choi, E Koumarianou, D Weitzel, ... Journal of Nuclear Medicine 57 (6), 967-973, 2016 | 75 | 2016 |
| Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation J Choi, G Vaidyanathan, E Koumarianou, CM Kang, MR Zalutsky Nuclear medicine and biology 56, 10-20, 2018 | 69 | 2018 |
| Radiolabeling and in vitro evaluation of 67Ga-NOTA-modular nanotransporter–A potential Auger electron emitting EGFR-targeted radiotherapeutic E Koumarianou, TA Slastnikova, M Pruszynski, AA Rosenkranz, ... Nuclear medicine and biology 41 (6), 441-449, 2014 | 64 | 2014 |
| 44Sc-DOTA-BN [2-14] NH2 in comparison to 68Ga-DOTA-BN [2-14] NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET? E Koumarianou, NS Loktionova, M Fellner, F Roesch, O Thews, D Pawlak, ... Applied Radiation and Isotopes 70 (12), 2669-2676, 2012 | 64 | 2012 |
| Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I TA Slastnikova, E Koumarianou, AA Rosenkranz, G Vaidyanathan, ... EJNMMI research 2, 1-10, 2012 | 47 | 2012 |
| Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation E Koumarianou, R Mikołajczak, D Pawlak, X Zikos, P Bouziotis, ... Nuclear medicine and biology 36 (6), 591-603, 2009 | 43 | 2009 |
| Comparison of receptor affinity of nat Sc-DOTA-TATE versus nat Ga-DOTA-TATE E Koumarianou, D Pawlak, A Korsak, R Mikolajczak Nuclear Medicine Review 14 (2), 85-89, 2011 | 35 | 2011 |
| Supported liquid membrane extraction of 177Lu (III) with DEHPA and its application for purification of 177Lu-DOTA-lanreotide K Kumrić, T Trtić-Petrović, E Koumarianou, S Archimandritis, JJ Čomor Separation and purification technology 51 (3), 310-317, 2006 | 31 | 2006 |
| N-Succinimidyl 3-((4-(4-[18 F] fluorobutyl)-1 H-1, 2, 3-triazol-1-yl) methyl)-5-(guanidinomethyl) benzoate ([18 F] SFBTMGMB): a residualizing label for 18 F-labeling of … G Vaidyanathan, D McDougald, J Choi, M Pruszynski, E Koumarianou, ... Organic & biomolecular chemistry 14 (4), 1261-1271, 2016 | 25 | 2016 |
| Synthesis and evaluation of 4-[18F] fluoropropoxy-3-iodobenzylguanidine ([18F] FPOIBG): A novel 18F-labeled analogue of MIBG G Vaidyanathan, D McDougald, E Koumarianou, J Choi, M Hens, ... Nuclear medicine and biology 42 (8), 673-684, 2015 | 22 | 2015 |
| N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization J Choi, G Vaidyanathan, E Koumarianou, D McDougald, M Pruszynski, ... Nuclear medicine and biology 41 (10), 802-812, 2014 | 21 | 2014 |
| D-amino acid peptide residualizing agents bearing N-hydroxysuccinimido-and maleimido-functional groups and their application for trastuzumab radioiodination M Pruszynski, E Koumarianou, G Vaidyanathan, S Chitneni, MR Zalutsky Nuclear medicine and biology 42 (1), 19-27, 2015 | 10 | 2015 |
| Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing … SK Chitneni, E Koumarianou, G Vaidyanathan, MR Zalutsky Molecules 24 (21), 3907, 2019 | 9 | 2019 |
| d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution M Pruszynski, CM Kang, E Koumarianou, G Vaidyanathan, MR Zalutsky Molecules 23 (5), 1223, 2018 | 9 | 2018 |
| Investigation of the 188Re Eluate Suitability for Medical Purposes by Labeling a Bombesin Analog (BN1. 1) E Koumarianou, R Mikolajczak, M Fiszer, D Pawlak, C Zikos, P Garnuszek, ... Current Radiopharmaceuticals 2 (4), 295-303, 2009 | 4 | 2009 |
| [211At] YC-I-27 for PSMA-targeted alpha-particle radiopharmaceutical therapy A Kiess, IL Minn, G Vaidyanathan, R Hobbs, A Josefsson, C Shen, ... Journal of Nuclear Medicine 57 (supplement 2), 143-143, 2016 | 2 | 2016 |
| A 211At-labeled nanobody for α-particle therapy of HER2-expressing cancers J Choi, G Vaidyanathan, E Koumarianou, T Lahoutte, M Zalutsky Journal of Nuclear Medicine 56 (supplement 3), 171-171, 2015 | 1 | 2015 |
michael zalutskyprofessorVerified email at mc.duke.edu
